Plaque Psoriasis Clinical Trials

495 clinical trials for Plaque Psoriasis across international registries, including 84 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD — RECRUITING
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis — RECRUITING · PHASE2
• An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis — RECRUITING · PHASE2
• Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis — RECRUITING
• A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period — RECRUITING · PHASE1
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — RECRUITING · PHASE3
• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis — RECRUITING · PHASE3
• Modifying PEST for Psoriatic Arthritis Screening — RECRUITING · NA
• Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — RECRUITING · PHASE2
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• A Phase 3 Clinical Study of QL2106 Injection — RECRUITING · PHASE3
• A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers — RECRUITING
• Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis — RECRUITING · PHASE1
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ORKA-001 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS — RECRUITING
• Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE2
• A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED DOSE-RANGE FINDING STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORKA-002 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS — RECRUITING
• MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED, DOSE-RANGE FINDING STUDY OF ORKA-001 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS — RECRUITING
• Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE3
• A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis — RECRUITING · NA
• A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE1
• A PHASE 3B/4 MULTI-CENTER, RANDOMIZED, OPEN-LABEL, LONG-TERM SAFETY STUDY OF DEUCRAVACITINIB IN COMPARISON TO USTEKINUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS (PRAGMATYK) — RECRUITING · PHASE3
• A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis — RECRUITING · PHASE1
• A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO -CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORKA-001 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS — RECRUITING
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OFDEUCRAVACITINIB IN ADOLESCENT PARTICIPANTS (12 YEARS TO LESS THAN 18YEARS) WITH MODERATE TO SEVERE PLAQUE PSORIASIS — RECRUITING · PHASE3
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis — RECRUITING · PHASE1
• ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar — RECRUITING
• A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND USTEKINUMAB ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-77242113 FOR THE TREATMENT OF PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS — RECRUITING · PHASE3
• A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis — RECRUITING
• AN EXTENSION STUDY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TO EVALUATE THE LONG-TERM SAFETY, EFFICACY, AND DURABILITY OF RESPONSE TO ESK-001 (ONWARD3/ESK-001-018) — RECRUITING
• Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis — RECRUITING · PHASE2
• A PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF TAK-279 IN SUBJECTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR CONTROLLED PHASE 3 STUDY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TO EVALUATE THE EFFICACY AND SAFETY OF ESK-001 — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE COMPARATOR (APREMILAST)-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ME3183 IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (BRING-1 STUDY) — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ESK-001 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (ONWARD1) — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS — RECRUITING
• A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) — RECRUITING
• A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DEUCRAVACITINIB ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-77242113 FOR THE TREATMENT OF PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS — RECRUITING · PHASE3
• A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DEUCRAVACITINIB ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ 77242113 FOR THE TREATMENT OF PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS — RECRUITING · PHASE3
• A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-77242113 FOR THE TREATMENT OF PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH RANDOMIZED WITHDRAWAL AND RETREATMENT — RECRUITING · PHASE3
• A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-77242113 FOR THE TREATMENT OF PARTICIPANTS WITH PLAQUE PSORIASIS INVOLVING SPECIAL AREAS — RECRUITING · PHASE3
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ESK-001 IN PATIENTS WITH PLAQUE PSORIASIS — RECRUITING
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VTX958 IN PARTICIPANTS WITH MODERATE TO SEVERE PSORIASIS — RECRUITING · PHASE2
• Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis — RECRUITING · PHASE4
• (OPTIMMIZE-2): A PHASE 3 MULTICENTER, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF RISANKIZUMAB IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO HAVE COMPLETED PARTICIPATION IN STUDY M19-977 (OPTIMMIZE-1) — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING-DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF XMAB®27564 IN PATIENTS WITH PLAQUE PSORIASIS — RECRUITING
• A PHASE 3 STUDY OF TAPINAROF FOR THE TREATMENT OF PLAQUE PSORIASIS IN PEDIATRIC SUBJECTS — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY AND SAFETY OF BMS-986165 IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS — RECRUITING · PHASE3
• A MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF TWO DOSES OF BIMEKIZUMAB IN ADOLESCENT STUDY PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (AMENDMENT 1) — RECRUITING

Refine this search